Healthcare
Tyra Biosciences, Inc.(TYRA)
Live Price
Offline$28.32
-2.58% today
1Y Change
+192.42%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $1.83B
- Revenue Growth
- 0.0%
- EPS Growth
- -33.1%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tyra Biosciences, Inc. (TYRA) is a Healthcare stock with a market cap of $1.83B and listed on NASDAQ. The stock last traded around $28.32 and up 192.4% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.1%, free cash flow -35.3% with operating margin 0.0% and ROIC -50.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TYRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -33.1%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.5% | -9.6% | -26.1% |
2026 Mar 2, 2026 | -5.6% | +1.5% | +3.8% | +6.4% |
2025 Nov 5, 2025 | +0.0% | -3.6% | +4.5% | +49.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TYRA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TYRA Max Drawdown
-35.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TYRA and SPY.
Company Overview
Tyra Biosciences, Inc.
NASDAQ Global Select
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
- Leadership
- Todd Harris
- IPO Date
- Sep 15, 2021
- Employees
- 60
- Street Address
- 2656 State Street
- Mailing
- Carlsbad, CA, 92008
- Region
- Carlsbad, CA, US
- Reporting Currency
- USD
- Investor Line
- 619 728 4760
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 7.8
Growth
- Revenue
- 0.0%
- EPS
- -33.1%
- Free Cash Flow
- -35.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -41.2%
- ROIC
- -50.1%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 14.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.